The Impact of Molecular Alterations in Advanced RAI-R-DTC Treatment Decision-Making

During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients with anaplastic thyroid cancer.

Noah S. Kalman, MD, MBA, highlighted advancements in thyroid cancer treatment, emphasizing personalized therapies, molecular testing, and optimizing traditional approaches.

The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary thyroid cancer in patients aged 2 years and older.

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a community oncologist should be aware of.